EP4117668A4 - Composition and method for oral treatment of leukemia - Google Patents

Composition and method for oral treatment of leukemia Download PDF

Info

Publication number
EP4117668A4
EP4117668A4 EP21935450.3A EP21935450A EP4117668A4 EP 4117668 A4 EP4117668 A4 EP 4117668A4 EP 21935450 A EP21935450 A EP 21935450A EP 4117668 A4 EP4117668 A4 EP 4117668A4
Authority
EP
European Patent Office
Prior art keywords
leukemia
composition
oral treatment
oral
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21935450.3A
Other languages
German (de)
French (fr)
Other versions
EP4117668A1 (en
Inventor
Aru NARENDRAN
Dominic Rodrigues
Bruce Horowitz
Edward V. PERSHING
Eric A. Wachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UTI LP
Provectus Pharmatech Inc
Original Assignee
UTI LP
Provectus Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UTI LP, Provectus Pharmatech Inc filed Critical UTI LP
Publication of EP4117668A1 publication Critical patent/EP4117668A1/en
Publication of EP4117668A4 publication Critical patent/EP4117668A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP21935450.3A 2021-04-16 2021-04-16 Composition and method for oral treatment of leukemia Pending EP4117668A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/027702 WO2022220841A1 (en) 2021-04-16 2021-04-16 Composition and method for oral treatment of leukemia

Publications (2)

Publication Number Publication Date
EP4117668A1 EP4117668A1 (en) 2023-01-18
EP4117668A4 true EP4117668A4 (en) 2023-12-06

Family

ID=83640921

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21935450.3A Pending EP4117668A4 (en) 2021-04-16 2021-04-16 Composition and method for oral treatment of leukemia

Country Status (8)

Country Link
EP (1) EP4117668A4 (en)
JP (1) JP7525638B2 (en)
KR (1) KR20230171854A (en)
CN (1) CN115955969A (en)
AU (1) AU2021440597A1 (en)
CA (1) CA3175637A1 (en)
MX (1) MX2022012945A (en)
WO (1) WO2022220841A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005812A1 (en) * 2000-07-14 2002-01-24 Photogen, Inc. Medicaments for chemotherapeutic treatment of disease
KR20070022308A (en) * 2004-05-10 2007-02-26 로버트 에프 호프만 Use of targeted oxidative therapeutic formulation in treatment of cancer
US20190350893A1 (en) * 2018-05-16 2019-11-21 Provectus Pharmatech, Inc. In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid Tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482347B (en) * 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 Modified antibody compositions, and methods of making and using thereof
US8765725B2 (en) * 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2018047917A1 (en) * 2016-09-09 2018-03-15 国立大学法人 東京大学 Synergistic antitumor effect of combination of hmg protein, anti-cd4 antibody or immune checkpoint control agent
CA3059882A1 (en) * 2017-04-12 2018-10-18 Aura Biosciences, Inc. Targeted combination therapy
AU2018254577B2 (en) * 2017-04-21 2024-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005812A1 (en) * 2000-07-14 2002-01-24 Photogen, Inc. Medicaments for chemotherapeutic treatment of disease
KR20070022308A (en) * 2004-05-10 2007-02-26 로버트 에프 호프만 Use of targeted oxidative therapeutic formulation in treatment of cancer
US20190350893A1 (en) * 2018-05-16 2019-11-21 Provectus Pharmatech, Inc. In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid Tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022220841A1 *
SWIFT LUCY ET AL: "In Vitro Activity and Target Modulation of PV-10 Against Relapsed and Refractory Pediatric Leukemia", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), pages 5207, XP086592718, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2018-99-119438 *

Also Published As

Publication number Publication date
JP7525638B2 (en) 2024-07-30
MX2022012945A (en) 2023-03-16
CA3175637A1 (en) 2022-10-20
EP4117668A1 (en) 2023-01-18
AU2021440597A1 (en) 2022-11-10
CN115955969A (en) 2023-04-11
WO2022220841A1 (en) 2022-10-20
KR20230171854A (en) 2023-12-21
JP2023529262A (en) 2023-07-10

Similar Documents

Publication Publication Date Title
EP4136254A4 (en) Ace2-targeted compositions and methods for treating covid-19
EP4110369A4 (en) Methods of treatment and related compositions
EP4230263A4 (en) Oral care additive, oral care composition, preparation method, kit, and application of oral care additive
EP4176902A4 (en) Oral pharmaceutical composition and method for producing same
EP4168425A4 (en) Methods and compositions for the treatment of muscular dystrophy
EP4138852A4 (en) Compositions and methods for the treatment of pain
EP4100029A4 (en) Compositions and methods of use thereof for treatment of mastitis
EP4045063A4 (en) Composition and method for treatment of multiple sclerosis
EP4034082A4 (en) Oral pharmaceutical immediate release composition and method of treatment for weight loss
EP4051260A4 (en) Methods and compositions for treatment of cancer
EP3958876A4 (en) Compositions and methods for treatment of cancer
EP4117668A4 (en) Composition and method for oral treatment of leukemia
EP3911358A4 (en) Methods and compositions for treatment of cancer
AU2021407382A9 (en) Compositions and methods for anxiety disorder treatment
EP4099997A4 (en) Methods and compositions for treatment of diseases
EP4135760A4 (en) Compositions and methods for treating leukemia
EP4175978A4 (en) Compositions and methods for treating crp-mediated diseases
EP3946420A4 (en) Methods and compositions for treatment of coronavirus infection and associated coagulopathy
EP3999077A4 (en) Composition and method for treatment of diabetes
EP4166157A4 (en) Composition for treatment of glutaric aciduria and administration method therefor
EP3976115A4 (en) Compositions and methods for treatment of hemochromatosis
EP4125920A4 (en) Methods and compositions for treatment of covid-19
AU2020901796A0 (en) Compositions and methods for treatment
EP4110923A4 (en) Methods and compositions for treatment of apc-deficient cancer
AU2022902622A0 (en) Methods of treatment and related compositions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221014

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20231108

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/02 20060101ALI20231102BHEP

Ipc: A61K 45/06 20060101ALI20231102BHEP

Ipc: A61K 31/522 20060101AFI20231102BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)